efgartigimod administration
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Myasthaenia Gravis
Conditions
Myasthaenia Gravis
Trial Timeline
Feb 6, 2025 → Jan 6, 2027
NCT ID
NCT06765161About efgartigimod administration
efgartigimod administration is a phase 3 stage product being developed by Argenx for Myasthaenia Gravis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06765161. Target conditions include Myasthaenia Gravis.
What happened to similar drugs?
0 of 1 similar drugs in Myasthaenia Gravis were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06765161 | Phase 3 | Recruiting |
Competing Products
1 competing product in Myasthaenia Gravis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Decartes-08 | Cartesian Therapeutics | Phase 3 | 37 |